Mecasermin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Mecasermin: From Severe Primary IGF-1 Deficiency to Monosomy X (Turner Syndrome)
One-Sentence Summary
Mecasermin (recombinant human IGF-1, DrugBank DB01277) is used for severe primary IGF-1 deficiency / growth failure due to growth hormone insensitivity. The TxGNN model predicts it may be effective for Monosomy X (Turner syndrome), but this direction is currently supported by no clinical trials and no published literature — it is a model-only prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Severe primary IGF-1 deficiency (GH receptor/signalling defect) — not confirmed by a registered product label; MOA and label data are not yet available |
| Predicted New Indication | Monosomy X (Turner syndrome) |
| TxGNN Prediction Score | 99.59% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available for this candidate. Based on known pharmacology, mecasermin is recombinant human IGF-1, approved for severe primary IGF-1 deficiency — a condition arising from growth hormone receptor or post-receptor signalling defects — where it bypasses the defective GH receptor pathway and directly stimulates growth via the IGF-1 axis.
Turner syndrome (monosomy X) commonly presents with short stature, and clinicians occasionally observe a suboptimal growth response to standard GH therapy in some patients, which provides a loose rationale for exploring IGF-1 pathway involvement. However, monosomy X is a chromosomal disorder, not itself an IGF-1 deficiency state, so this link is an indirect inference about the growth axis rather than a direct molecular mechanism match. By comparison, another candidate in this evidence pack — growth hormone insensitivity syndrome with immune dysregulation — sits much closer to mecasermin’s approved mechanism (GH receptor/IGF-1 axis defect), though the immune-dysregulation subtype itself remains unvalidated.
Given the absence of any clinical trial or literature evidence specific to mecasermin in monosomy X, this prediction should be treated as a hypothesis-generating signal only, not as evidence of clinical efficacy.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
Mecasermin is not currently marketed in Australia and has no ARTG entries on record. No approved product information is available to reference for local labelling, indications, or dosing.
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information. No warnings, contraindications, or drug interaction data are currently available for this candidate in the evidence pack.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication is supported only by a TxGNN model score (Evidence Level L5) with zero clinical trials, zero publications, and no Australian market presence. Core safety data (warnings/contraindications) are also missing and flagged as a blocking data gap, so this candidate cannot yet proceed to a safety pre-assessment.
To proceed, the following is needed:
- TGA/TFDA Product Information — warnings, contraindications, and safety data (DG001, blocking)
- Documented mechanism of action for mecasermin (DG002)
- Confirmed original approved indication and label text (currently absent from structured regulatory data)
- Any preclinical or mechanistic studies linking IGF-1 signalling to Turner syndrome growth outcomes, to move evidence beyond L5
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.